Inc. (2011), Chairman at Fate Therapeutics, Inc. (2012), Chairman at Daré Bioscience, Inc. (2019), Chairman at San Diego Squared, Director at CONNECT, Independent Director at Regulus Therapeutics ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could ...

Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

As of 15:41:20 GMT-4. Market open.

At close: May 12 at 4:00:02 PM EDT ...

InteRNA is one of a growing number of biotech companies focusing on microRNA drug pipelines, along with the likes of miRagen, MiRNA Therapeutics, and Regulus Therapeutics. While InteRNA has taken ...

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, May 19, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene ...

CRISPR Therapeutics stock is down more than 80% from the peak it reached in 2021. The first drug from CRISPR Therapeutics launched early last year, but annualized sales are still less than $60 ...

The Company continues to work with Nuton to evaluate Nuton's proprietary sulphide bio-leaching technologies at the AntaKori project. The Phase One program identified that material from AntaKori was ...

Retail giants Home Depot and Lowe's are set to report earnings this week. Euro area’s core CPI will be released on Monday, and UK’s on Wednesday. See more here.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.